Barbara Ryan - Eloxx Pharmaceuticals Investor Officer
| ELOXDelisted Stock | USD 6.12 0.30 4.67% |
Insider
Barbara Ryan is Investor Officer of Eloxx Pharmaceuticals
| Phone | 781 577 5300 |
| Web | https://www.eloxxpharma.com |
Eloxx Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.7318) % which means that it has lost $0.7318 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (6.1523) %, meaning that it created substantial loss on money invested by shareholders. Eloxx Pharmaceuticals' management efficiency ratios could be used to measure how well Eloxx Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Eloxx Pharmaceuticals currently holds 13.38 M in liabilities. Eloxx Pharmaceuticals has a current ratio of 1.59, which is within standard range for the sector. Debt can assist Eloxx Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Eloxx Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Eloxx Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Eloxx to invest in growth at high rates of return. When we think about Eloxx Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| CPA CTP | Cns Pharmaceuticals | 44 | |
| Covadonga Paeda | Altamira Therapeutics | N/A | |
| Peter Facchini | Enveric Biosciences | 60 | |
| JD MBA | Immix Biopharma | N/A | |
| RPh PharmD | Elevation Oncology | 40 | |
| Diane Esq | Windtree Therapeutics | 55 | |
| Donald Picker | Cns Pharmaceuticals | 78 | |
| Brian Sullivan | Elevation Oncology | N/A | |
| Claus Pedersen | Allarity Therapeutics | 52 | |
| Narayan Prabhu | Reviva Pharmaceuticals Holdings | 52 | |
| Professor MD | Allarity Therapeutics | 67 | |
| Robert McRae | Palisade Bio | N/A | |
| Waldemar Priebe | Cns Pharmaceuticals | N/A | |
| Joan Brown | Allarity Therapeutics | 70 | |
| John CPA | Unicycive Therapeutics | 62 | |
| MBA IV | Enveric Biosciences | 68 | |
| Nandan BS | Immix Biopharma | 62 | |
| David Dornan | Elevation Oncology | 46 | |
| Gabriel BA | Immix Biopharma | 37 | |
| Joseph Tucker | Enveric Biosciences | 55 | |
| MD FAAAAI | Palisade Bio | N/A | |
Management Performance
| Return On Equity | -6.15 | ||||
| Return On Asset | -0.73 |
Eloxx Pharmaceuticals Leadership Team
Elected by the shareholders, the Eloxx Pharmaceuticals' board of directors comprises two types of representatives: Eloxx Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Eloxx. The board's role is to monitor Eloxx Pharmaceuticals' management team and ensure that shareholders' interests are well served. Eloxx Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Eloxx Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Vijay MBBS, Head RD | ||
| Barbara Ryan, Investor Officer | ||
| Ali MD, Chief Officer | ||
| MBA MBA, Principal CFO | ||
| Matthew Goddeeris, VP Research | ||
| Sumit MBA, CEO Pres |
Eloxx Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Eloxx Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -6.15 | ||||
| Return On Asset | -0.73 | ||||
| Current Valuation | 30.28 M | ||||
| Shares Outstanding | 2.75 M | ||||
| Shares Owned By Insiders | 0.59 % | ||||
| Shares Owned By Institutions | 37.06 % | ||||
| Number Of Shares Shorted | 21.48 K | ||||
| Price To Earning | (7.94) X | ||||
| Price To Book | 6.31 X | ||||
| EBITDA | (34.42 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Other Consideration for investing in Eloxx Pink Sheet
If you are still planning to invest in Eloxx Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eloxx Pharmaceuticals' history and understand the potential risks before investing.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |